In 40 seconds
Multiple Sclerosis (MS) affects more than 130,000 people in the UK. The four main types are relapsing-remitting (RRMS, ~85%), secondary progressive (SPMS), primary progressive (PPMS), and clinically isolated syndrome (CIS). UK care follows NICE NG220 — disease-modifying therapy from a neurology team plus symptom-specific care for fatigue, spasticity, walking, bladder, mood and cognition. PEMF is a non-pharmacological adjunct studied for fatigue, walking distance, mood, and global quality of life. It does not modify disease progression.
Quick facts
- UK prevalence: ≈ 130,000+ people
- Most common type: Relapsing-remitting MS (RRMS, 85%)
- Standard care: Neurology team — DMT + MS nurse + physio + OT per NICE NG220
- Best PEMF evidence for: Fatigue, walking distance, mood, sleep, paresthesia
- Sessions: 30–40 minutes, 2–3× per week for 6–8 weeks
- Speak to first: Your MS nurse or neurologist — keep DMT unchanged
What MS does
Multiple Sclerosis is an autoimmune condition in which the immune system attacks the myelin sheath insulating nerve fibres in the brain and spinal cord. The resulting demyelination disrupts nerve signal transmission across multiple systems. The disease courses are heterogeneous — some people experience attacks ("relapses") that resolve, others a steadily progressive picture, others a mix.
UK NHS care is delivered through specialist MS centres and community teams. The mainstays are disease-modifying therapy (DMT) from a neurology team — interferons, glatiramer, oral DMTs (teriflunomide, fingolimod, ozanimod, dimethyl fumarate), and high-efficacy infusions (natalizumab, ocrelizumab, alemtuzumab) — plus symptom-specific care from MS nurses, physiotherapists, occupational therapists, continence advisers and pain specialists.
PEMF therapy fits in as a non-pharmacological symptomatic adjunct. It does not replace any of the above, but a growing body of evidence suggests it can reduce fatigue, improve walking distance, support mood, and modestly improve quality of life.
How PEMF may help MS
- Fatigue — the most disabling MS symptom for many people. PEMF appears to support mitochondrial energy production and modulate the inflammatory load that drives fatigue.
- Walking — small studies report increased walking distance after PEMF courses, plausibly linked to reduced spasticity and improved fatigue.
- Mood — depression and anxiety affect 40–50% of MS patients. PEMF's autonomic and HRV effects are relevant here.
- Sleep — disrupted sleep is common in MS; PEMF's sleep benefits transfer.
- Paresthesia and neuropathic pain — pulsed magnetic fields appear to dampen the aberrant signalling that produces pins-and-needles and burning sensations.
Typical UK protocol
| Phase | Frequency | Duration | Goal |
|---|---|---|---|
| Trial | 2× per week | 3 weeks | Tolerability + baseline MSIS-29 / fatigue scale |
| Loading | 2–3× per week | 4–6 weeks | Fatigue, walking, sleep, mood |
| Maintenance | 1× per week or fortnight | Ongoing | Sustain response |
Use the MSIS-29 (Multiple Sclerosis Impact Scale) and a walking measure (timed 25-foot walk, or six-minute walk if you do regular physio). Without numbers you can't judge whether PEMF is moving symptoms.
Avoid sessions during an active relapse. Wait until the relapse is being managed and your condition is stable.
What the evidence shows
- Small randomised trials report fatigue and quality-of-life improvements after 4–8 weeks of regular PEMF in MS patients.
- Walking distance gains are reported but the studies are small.
- Relevant to mood and cognitive symptoms via the autonomic and sleep mechanisms.
- The MS Society UK takes a measured stance: PEMF is among the non-pharmacological adjuncts patients increasingly try; the evidence is not yet strong enough for NICE inclusion.
- The honest UK position: PEMF is a credible adjunct alongside DMT and physiotherapy, particularly for fatigue-dominant MS, but should never replace specialist neurology care.
Practical advice before booking
- Tell your MS nurse — not because PEMF interacts with DMT (it doesn't), but because they want a complete picture.
- Avoid sessions during a relapse — wait until stable.
- Heat sensitivity (Uhthoff's phenomenon) — confirm clinic temperature with the practitioner; some patients are sensitive to even mild warmth.
- Don't stop your DMT — disease-modifying therapy is non-negotiable. PEMF is symptomatic adjunct, not disease-modifying.
- Track MSIS-29 and walking — without numbers you can't evaluate.
Related guides on PEMF UK
PEMF for MS pain and spasticity
Detail on the pain and spasticity sub-aspect of MS.
RelatedPEMF for peripheral neuropathy
Different condition but overlapping nerve mechanisms.
SymptomPEMF for insomnia and sleep
Sleep is commonly disrupted in MS.
Contraindications
Hard exclusions — do not have PEMF if any apply:
- Pacemaker, implantable cardioverter-defibrillator (ICD), or any cardiac electronic device
- Cochlear implant or other implanted electronic hearing device
- Spinal cord stimulator, deep-brain stimulator, vagus nerve stimulator
- Intrathecal pump or implanted drug pump
- Insulin pump (continuous glucose monitors are usually fine — confirm with the clinic)
- Active infection at the treatment site
- Pregnancy — when treatment would be over the abdomen, lumbar spine, or pelvis
Discuss with your GP or specialist before booking if any apply:
- Active malignancy or recent cancer history (oncologist clearance required)
- History of seizures or epilepsy
- Multiple sclerosis or other neurological condition under specialist care
- Anticoagulant therapy (PEMF itself does not thin blood, but bruising risk if local circulation is already compromised)
- Children under 14 (most UK clinics will not treat under-18s without paediatric specialist input)
- Recent surgery within the last 14 days at the treatment site (confirm with surgeon)
NOT contraindications — these are commonly misunderstood:
- Plates, rods, screws and other passive metal orthopaedic hardware
- Dental implants and dental crowns
- Joint replacements (hip, knee, shoulder)
- IUDs (copper or hormonal)
- Tattoos and piercings (jewellery should be removed for the session)
Specific to this condition: Discuss PEMF with your MS specialist before starting. Avoid sessions during an active MS relapse. If you experience heat sensitivity (Uhthoff's phenomenon), confirm the treatment-room temperature with the clinic.
Frequently asked questions
Does PEMF treat MS?
No. PEMF is a non-pharmacological adjunct for symptomatic relief — primarily fatigue, walking, sleep and mood. It does not modify disease progression and is not a substitute for disease-modifying therapy.
Will it interact with my DMT?
There are no documented interactions between PEMF and any disease-modifying therapy or symptomatic medication. Tell your MS nurse you're using it for a complete picture.
How long before I know it's working?
Most UK clinics suggest 6 weeks of 2–3 sessions per week with MSIS-29 and walking measures tracked. If no change at 6 weeks the response is unlikely to develop later.
Can I have PEMF during a relapse?
We recommend waiting until the relapse is being actively managed. Use the relapse phase to engage your neurology team, not to start a new therapy.
Is PEMF cleared for MS in the UK?
PEMF is not NICE-recommended for MS specifically. It's available privately as a wellness adjunct — clinics should not market it as an MS treatment.
What's the UK cost?
Typical UK private clinic pricing is £40–£90 per session. A 6-week trial costs £400–£600 in total.
Find a PEMF clinic near you
We list every credible PEMF therapy provider in the UK so you can find one near home.